Impact of gene expression signatures of immune infiltration on response to sequential intravesical gemcitabine and docetaxel versus bacillus Calmette-Guerin in high-risk non-muscle-invasive bladder cancer.
Vignesh T. Packiam(Rutgers, The State University of New Jersey), Michael A. O’Donnell(University of Iowa Health Care), Saum Ghodoussipour(Rutgers, The State University of New Jersey), Joep de Jong(Erasmus MC Cancer Institute), James A. Proudfoot(Veracyte (United States)), Ian M. McElree(Vanderbilt University Medical Center), Elai Davicioni(Coherus BioSciences (United States))
Cited by 0
Related Papers
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
|European Urology|2017|793
Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer
|Clinical Cancer Research|2018|126
Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non–Muscle-Invasive Bladder Cancer
|JAMA Network Open|2023|116